Avoid Mishaps With SGLT2 Inhibitors

September 2022

More inpatients will get SGLT2 inhibitors...canagliflozin, dapagliflozin, empagliflozin, or ertugliflozin.

These meds were originally approved for type 2 diabetes. But now they’re also recommended for certain patients with heart failure.

Avoid mishaps with SGLT2 inhibitors as use increases.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

  • Cutting-edge advice about new medications and how they fit into practice
  • Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
  • Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Already a subscriber? Log in

Volume pricing available. Get a quote